Results 361 to 370 of about 304,614 (388)

Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist.

Journal of Pharmacology and Experimental Therapeutics, 1994
M. Clozel, V. Breu, G. Gray, B. Kalina, B. Löffler, K. Burri, J. Cassal, G. Hirth, Marcel Muller, Werner L. Neidhart   +9 more
semanticscholar   +1 more source

Treatment of muscle‐invasive and advanced bladder cancer in 2020

Ca-A Cancer Journal for Clinicians, 2020
Vaibhav G Patel, William K Oh, Matthew D Galsky   +2 more
exaly  

Tumor board presentation of a woman with metastatic, hormone receptor‐positive, mismatch repair‐deficient endometrial cancer

Ca-A Cancer Journal for Clinicians, 2022
Gini F Fleming, Jennifer A Bennett
exaly  

Evolving standards of care and new challenges in the management of HER2‐positive breast cancer

Ca-A Cancer Journal for Clinicians, 2020
Ciara C O’sullivan, Grace D Cullen, Grace M Choong   +2 more
exaly  

Pharmacology of Macitentan, an Orally Active Tissue-Targeting Dual Endothelin Receptor Antagonist

Journal of Pharmacology and Experimental Therapeutics, 2008
M. Iglarz, C. Binkert, K. Morrison, W. Fischli, J. Gatfield, A. Treiber, T. Weller, M. Bolli, C. Boss, Stephan Buchmann, Bruno Capeleto, P. Hess, C. Qiu, M. Clozel   +13 more
semanticscholar   +1 more source

Ambrisentan, an endothelin receptor type A-selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension

Expert Opinion on Pharmacotherapy, 2009
M. Kingman, R. Ruggiero, F. Torres
semanticscholar   +1 more source

Breast Cancer—Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual

Ca-A Cancer Journal for Clinicians, 2017
Elizabeth A Mittendorf, Hope S Rugo, Gabriel N Hortobagyi   +2 more
exaly  

Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist

Nature, 1993
M. Clozel, V. Breu, K. Burri, J. Cassal, W. Fischli, G. Gray, G. Hirth, Bernd-Michael Löffier, Marcel Müller, Werner L. Neidhart, H. Ramuz   +10 more
semanticscholar   +1 more source

Effects of bosentan, an endothelin receptor antagonist, on bile salt export pump and multidrug resistance–associated protein 2

Biopharmaceutics & drug disposition, 2007
Yuji Mano, T. Usui, H. Kamimura
semanticscholar   +1 more source

Obesity and adverse breast cancer risk and outcome: Mechanistic insights and strategies for intervention

Ca-A Cancer Journal for Clinicians, 2017
Joyce Slingerland, Manuel Picon-ruiz, Cynthia Morata-tarifa   +2 more
exaly